Ogura Y, Kawaguchi Y, Sakai S, Yamamoto M, Kimura Y, Oda Y, Imamura N, Tsukui I
Contrib Nephrol. 1980;22:18-27. doi: 10.1159/000385984.
Plasma levels of 25-OH-D, 1,25-(OH)2-D and 24,25-(OH)2-D in acute renal failure, chronic glomerulonephritis and chronic renal failure were determined by competitive protein binding assay and evaluated for the correlation with the degree of renal impairment and the influence of dialysis, renal transplantation and the administration of vitamin D and 1-alpha-OH-D3. In this study it is revealed that 25-OH-D deficiency could be normalized by the administration of vitamin D2. Plasma levels of 1,25-(OH)2-D are decreased in proportion to the degree of renal impairment and it is clearly depressed in patients, with a Ccr of 30 ml/min or less. Although biosynthesis of 24,25-(OH)2-D is not remarkably depressed, it is necessary to resolve various questions including the methods of measurement in this respect. It is also disclosed in the present study that 1-alpha-OH-D3 is faster in action than vitamin D2 when used to correct 1,25-(OH)2-D3 deficiency.
采用竞争性蛋白结合分析法测定急性肾衰竭、慢性肾小球肾炎和慢性肾衰竭患者血浆中25-羟基维生素D、1,25-二羟基维生素D和24,25-二羟基维生素D的水平，并评估其与肾功能损害程度的相关性以及透析、肾移植以及维生素D和1-α-羟基维生素D3给药的影响。本研究表明，给予维生素D2可使25-羟基维生素D缺乏恢复正常。1,25-二羟基维生素D的血浆水平与肾功能损害程度成比例降低，当肌酐清除率为30 ml/min或更低时，患者体内该水平明显降低。虽然24,25-二羟基维生素D的生物合成没有明显降低，但在这方面仍有必要解决包括测量方法在内的各种问题。本研究还表明，在纠正1,25-二羟基维生素D3缺乏时，1-α-羟基维生素D3的作用比维生素D2更快。
